Sandostatin
(Octreotide Acetate)Phase 3Small molecule
Sun Pharmaceutical Industries, Inc.Octreotide is used to control symptoms of certain hormone-producing tumors and to reduce fluid loss in patients with severe diarrhea. It works by mimicking a natural body hormone that slows down the release of other hormones and reduces intestinal movement.[1] Sandostatin is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Sandostatin is one of 101 small molecule programs targeting Metastasis. It is currently in Phase 3.
4
Indications
31
Total Trials
2
Active Trials
100
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Insulin Resistance
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Glucophage
EMD SeronoApproved
Niacor
AbbVieApproved
Sovaldi
GileadApproved
Isordil
AstraZenecaApproved
Plaquenil
Jazz PharmaceuticalsApproved
Tradjenta
Boehringer IngelheimApproved
Starlix
NovartisApproved
Victrelis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Glucophage
EMD SeronoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diarrhea4 trials
Acromegaly3 trials
Neuroendocrine Tumors2 trials
Thymoma1 trial
20 more indications
Neuroendocrine Carcinoma1 trial
Dexamethasone1 trial
Dexamethasone/Pancreatic Clamp P&F
Withdrawn·—·Phase 1·NCT06126354
Lymphoma1 trial
Metastatic Neuroendocrine Tumor1 trial
Insulin resistance1 trial
Human Models of Selective Insulin Resistance: Pancreatic Clamp
Not yet recruiting·—·Phase 1·NCT06558422·36 enrolled
Pancreatic1 trial
Pancreatic Clamp in NAFLD
Completed·—·Phase 1·NCT05724134·18 enrolled
Interaction1 trial
Gastrointestinal1 trial
Colorectal Cancer1 trial
Surgery1 trial
Breast Cancer1 trial
Neuroendocrine Tumor1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Oct 21, 1988
SANDOSTATIN
NDA NDA019667
Nov 25, 1998
SANDOSTATIN LAR
NDA NDA021008
Jun 26, 2020
MYCAPSSA
NDA NDA208232
Sep 27, 2024
BYNFEZIA PEN
NDA NDA213224
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Octreotide Acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details